Complex Neurological Phenotype in Female Carriers of NHE6 Mutations

Matthew F. Pescosolido a–d  Brian C. Kavanaugh c, d  Nathalie Pochet e–g  Michael Schmidt a–d  Beth A. Jerskey c  Jeffrey M. Rogg h  Philip L. De Jager e–g  Tracy L. Young-Pearse e  Judy S. Liu a, i  Eric M. Morrow a–d

a Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA; b Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, RI, USA; c Developmental Disorders Genetics Research Program, Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University and Emma Pendleton Bradley Hospital, East Providence, RI, USA; d Hassenfeld Child Health Innovation Institute, Brown University, Providence, RI, USA; e Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA, USA; f Department of Neurology, Harvard Medical School, Boston, MA, USA; g Cell Circuits Program, Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA; h Department of Diagnostic Imaging, Warren Alpert Medical School of Brown University, Providence, RI, USA; i Department of Neurology, Rhode Island Hospital, Providence, RI, USA

Keywords
Na+/H+ exchanger 6 (NHE6) · X-chromosome inactivation (XCI) · Christianson syndrome · Female carriers

Abstract
Mutations in NHE6 (also termed SLC9A6) cause the X-linked neurological disorder Christianson syndrome (CS) in males. The purpose of this study was to examine the phenotypic spectrum of female carriers of NHE6 mutations. Twenty female carriers from 9 pedigrees were enrolled, ranging from approximately age 2 to 65. A subset of female carriers was assessed using standardized neuropsychological measures. Also, the association of NHE6 expression with markers of brain age was evaluated using 740 participants in the Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP). A majority, but not all, female carriers demonstrated a deficit in at least one neurocognitive domain (85%). A recognizable neuropsychological profile emerged, revealing impairments in visuospatial function, attention, and executive function. Common neuropsychiatric diagnoses included: intellectual disability/developmental delay (20%), learning difficulties (31%), speech/language delays (30%), and attention-deficit/hyperactivity disorder (20%). Notable neurological diagnoses in aging CS female carriers include corticobasal degeneration and atypical parkinsonism. In postmortem brains from the ROS/MAP dataset of normal and pathological aging, decreased NHE6 expression was correlated with greater tau deposition. Our study provides an examination of the phenotypic range in female carriers of NHE6 mutations. The findings indicate that NHE6-related disease in females represents a new neurogenetic condition.

© 2019 S. Karger AG, Basel

M.F.P. and B.C.K. contributed equally to this work.
Introduction

Christianson syndrome (CS) is a monogenic, X-linked neurological disorder caused by mutations in the gene encoding endosomal Na+/H+ exchanger 6 (NHE6) (also known as SLC9A6) [1]. NHE6 proteins are generally 12-transmembrane-domain proteins that exchange hydrogen ions for cations (e.g., Na+ or K+ ions). Affected CS males usually harbor loss-of-function mutations and present with intellectual disability (ID)/developmental delay (DD), epilepsy, postnatal microcephaly, and ataxia [1–4]. Notable neurological symptoms reported in a subset of CS patients include cerebellar/brainstem atrophy and eye movement problems (closest to Duane syndrome Type I, i.e. an inward gaze deviation), as well as regressions in adaptive and/or motor functioning [2, 3, 5]. Female carriers in these CS pedigrees exhibit heterogeneous phenotypes, ranging from unaffected to presenting with mild-moderate ID/DD, neuropsychiatric disorders including attentional difficulties, mild ataxia, and/or microcephaly [1–8]. Recurrent developmental features of female carriers include learning problems, difficulty in school, speech disorder, and/or behavioral problems [2–4, 7]. However, the full phenotypic spectrum in females with NHE6 mutations, particularly across the lifespan, is currently unknown.

Progressive symptoms, some potentially reflecting neurodegeneration, have been identified in CS males. For example, symptoms that may develop and/or worsen with age include cerebellar/brainstem atrophy, motor decline/ataxia, cognitive/behavioral regressions, and low weight/height [2, 3, 9]. Postmortem examination of 2 CS males in their 40s and 50s found widespread neuronal and glial loss, as well as accumulation of tau-positive tangle-like inclusions [9]. Furthermore, neurodegenerative features have been reported in an Nhe6-null mouse model such as loss of Purkinje cells in the cerebellum, loss of tissues and synapses, and a strong microglial response [10].

The wide phenotypic spectrum reported in girls and women who are carriers of NHE6 mutations is consistent with other X-linked conditions wherein the tissues of female carriers are likely mosaic for gene expression (with a variable proportion of cells expressing from the mutant gene locus) based on random X-chromosome inactivation. Indeed, female Nhe6-heterozygous mice exhibit similar, yet less severe, neurological and motor phenotypes as Nhe6-null male mice [11]. As part of an international CS registry, we enrolled the largest cohort of female carriers (20 participants) across multiple CS pedigrees (n = 9). We conducted standardized assessments to ascertain the range and severity of neurological and adaptive symptoms in female carriers. To investigate the cognitive profile of female carriers, neuropsychological testing was conducted on 13 female carriers from 7 pedigrees. Given progressive features in CS male probands and Nhe6-null mice, neurological histories and brain imaging from CS female carriers at age 50 years or older were assessed. Finally, the relationship between NHE6 expression and neurodegenerative characteristics was examined using brain transcriptome data from two large normal aging and dementia cohorts. The brain transcriptome analysis included brain samples from 740 participants enrolled in the Religious Orders Study (ROS) [12] and the Rush Memory and Aging Project (MAP) [13].

Materials and Methods

Participants

Institutional Review Boards at Brown University and Lifespan Healthcare approved this research. All participants provided written informed consent. Female carriers were identified as part of an international CS registry [2]. Clinical information was collected by direct interviews with participants and from available medical records. DNA was isolated from either blood or saliva from all female carriers. Heterozygosity for an NHE6 mutation known to cause CS in a related male was confirmed in participating females by sequencing all coding exons (1–16) and exon/intron junctions, as previously described [2]. Some pedigree features have been changed to assure anonymity.

Neuropsychological Assessments

Neuropsychological function was assessed in a subset of available participants. Neurocognition in adults (i.e., ≥18 years old) was assessed by the following measures: Wechsler Abbreviated Scales of Intelligence-Second Edition (WASI-II), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Trail Making Test A&B (TMT A&B), Controlled Oral Word Association Test (COWAT), and Mini-Mental State Exam (MMSE). Neurocognition in children (i.e., <18 years old) was measured using the following assessments: A Developmental Neuropsychological Assessment-Second Edition (NEPSY-II), Wechsler Preschool Primary Scales of Intelligence-Fourth Edition (WPPSI-IV), WASI-II, Children’s Memory Scales (CMS), TMT A&B, Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV), Rey Complex Figure Test (RCFT), Beery-Buktenica Developmental Test of Visual-Motor Integration (Beery), and COWAT. Domain composite scores were calculated to assess IQ (RBANS), language (RBANS, WPPSI-IV), visuospatial function (RBANS, NEPSY-II, RCFT, Beery), attention (RBANS, WPPSI-IV, WISC-IV), memory (RBANS, NEPSY-II, CMS), and executive function (TMT A&B, COWAT, NEPSY-II).
Brain Transcriptome Data

*NHE6* expression in brain was analyzed from two aging and dementia cohorts – ROS [12] and MAP [13]. Postmortem brain specimens were collected from 740 participants and analyzed by researchers affiliated with these studies (N.P., T.L.Y.-P., P.L.D.J.). Data collection and methods for this analysis have been reported elsewhere [14] and are briefly summarized. RNA-Seq expression data were obtained from gray matter of the dorsolateral prefrontal cortex. RNA extraction was performed with Qiagen’s miRNAeasy mini kit and RNase-free DNase. An RNA-Seq library was curated via a strand-specific dUTP method [15] with poly-A selection [16]. Finally, sequencing was performed on an Illumina HiSeq platform using 50 million paired-end reads at 101 bp.

Alzheimer’s disease (AD)-related neuropathological findings such as neurofibrillary tangles, diffuse plaques, and neuritic plaques have been detailed elsewhere [14]. Immunohistochemical techniques employed the Avidin-Biotin Complex staining method, using alkaline phosphatase as the color developer. For Aβ and tau accumulation, 20-μm tissue sections from 8 brain regions were analyzed: entorhinal cortex, CA1/subiculum of the hippocampus, superior frontal cortex, mid-prefrontal cortex, inferior temporal cortex, angular gyrus, anterior cingulate cortex, and calcarine cortex. Images for neocortical (90 images) and non-neocortical (20 images) of Aβ-stained sections were quantified using an automated analysis. Aβ mean percentage was quantified as the percentage of area with amyloid and calculated both within and across each brain region. Tau abundance was quantified as the density of tangles per mm² and averaged both within and across each brain region.

*NHE6* Sequencing in Females with Idiopathic Parkinson-Related Syndromes

Female samples from the National Institute of Neurological Disorders and Stroke neurodegeneration biorepository were sequenced for *NHE6* variants. A total of 156 samples were sequenced from females diagnosed with either progressive supranuclear palsy (PSP) (n = 150) or corticobasal degeneration (CBD) (n = 6) (online suppl. Table 1; see www.karger.com/doi/10.1159/000496341 for all online suppl. material). All exons and 15–20 bp into exon/intron junctions (i.e., to accurately identify splice variants) were sequenced in the *NHE6* gene. PCR was performed for *NHE6* target enrichment using the Fluidigm platform. GC-rich exon 1, however, was Sanger sequenced using the following primers: 5′-TTGTGTTACACTGAGCCGATG-3’ (forward) and 5′-AACCGAAA-AAGGTGTTGGAGA-3’ (reverse). Samples were sequenced using the MiSeq platform (Illumina). Raw read sequences were analyzed and clipped using Trimmomatic version 0.32 [17]. Reads were not included in variant analysis if they met any of the following criteria: possible adapter sequences, low quality bases of single reads (Phred score <20), reads with low average quality threshold (window size 4 bp, Phred score <20), reads clipped at bases with a Phred Score <3, and clipped reads shorter than a threshold length of 80 bp. Reads were mapped using BWA-MEM version 0.7.10 (http://bio-bwa.sourceforge.net). Filtered read pairs were mapped to their ampiclon sequences, not the entire human genome, to prevent mislabeling pseudogenes and additional loci with similar sequences. Variant analysis was conducted by VarScan version 2.3.6 [18]. Reads with ≥1 Phred Quality Score were analyzed. Single nucleotide polymorphisms and insertions or deletions (indels) were annotated by snpEff version 4.0 [19]. The pathogenicity of missense variants was assessed in silico using PolyPhen-2 [20]. All potentially deleterious variants identified via MiSeq were confirmed by Sanger sequencing.

Results

Female Carriers Identified from CS Cohort

A total of 20 female carriers of *NHE6* mutations were enrolled across 9 pedigrees. All mutations were predicted to be loss-of-function and were identified in pedigrees wherein there was at least one hemizygous male with the same mutation who was affected with CS. Mean age of female carriers was 30.3 ± 17.6 years, with an age range spanning from approximately 2 years to 65 years. Five non-carrier females across four CS pedigrees were also enrolled to serve as a familial control. The mean age for non-carrier females was 29.7 ± 21.1, with an age range spanning from approximately age 10 years to 75 years. When possible, neuropsychological testing was performed on a subset of female carriers and non-carriers in CS pedigrees. A total of 13 carriers and 3 non-carriers from 7 CS pedigrees were assessed. Mean carrier age of those with direct neuropsychological assessment was 30.1 ± 15.9 years, with a range of approximately 3 years to 55 years. Mean non-carrier age of those assessed was 21.7 ± 18.5 years, with a range of approximately age 10 years to 45 years.

Neuropsychological Performance in Female Carriers

Most female carriers (85%) demonstrated deficits in at least one neurocognitive domain (Fig. 1a; Table 1). Deficits were defined as standardized, age-normed z-scores <–1.5. A majority of female carriers demonstrated deficits in two or more domains (69%). Notable impaired cognitive domains included: visuospatial function (62%), attention (62%), and executive function (54%). Almost all female carriers exhibited a deficit in at least one of these three domains (92%, 12 out of 13), while a large proportion of individuals had co-occurring deficits in all three
domains (39%, 5 out of 13) (Fig. 1b). Deficits in language function were less common (25%). Approximately one-third of female carriers tested had an overall full-scale IQ < 70 (31%, 4 out of 13). We further tested if an effect of age could be discerned in this cross-sectional dataset. A distribution of participants’ ages at time of enrollment and testing is shown (Fig. 2a, b). We compared neurocognitive functioning in pediatric (< 18 years old) and adult (≥18 years old) female carriers. No significant age-related correlations in performance across any domain were found (Fig. 2). Neurocognitive data were also collected on 3 non-carrier female family members, all of whom performed generally without impairment. Given the small sample size of non-carriers, it is currently difficult to establish comparison of carriers to non-carriers so as to assess deficit relative to familial expectation. Therefore, comparisons to standardized controls are presented (i.e., z-scores).

Neuropsychiatric and Age-Related Symptoms in Female Carriers

Notable neurological and neuropsychiatric features were also present in female NHE6 mutation carriers (Table 2). One-fifth of female carriers (20%) were diagnosed with ID/DD, which occurred in almost half of the pedigrees in this female carrier cohort (44%). Of those female
Fig. 2. Neurocognitive profile of pediatric (i.e., < 18 years old) and adult (i.e., ≥ 18 years old) female carriers of NHE6 mutations. 

**a** Age distribution of all enrolled female carriers (i.e., age at enrollment). 

**b** Age distribution of female carriers with neurocognitive assessments (i.e., age at testing). 

**c–i** Comparison of pediatric versus adult female carriers across neurocognitive domains. Pearson correlation analyses were conducted to examine the association between age (i.e., pediatric or adult) and neurocognition. There were no statistically significant age effects found in any domain. Ages of pediatric female carriers (n = 4) ranged from approximately 4–17 years (average age 10.3 ± 4.6 years); ages of adult female carriers (n = 9) ranged from approximately 25–55 years (average age 38.9 ± 9.3 years). All neurocognitive domains were assessed in the 4 pediatric participants, except for language (n = 3). Neurocognitive data are reported as mean ± SEM.
carriers not diagnosed with ID/DD, 31% were noted to have learning difficulties. Additional features present in more than one female carrier included: speech/language delays (30%), attention-deficit/hyperactivity disorder (20%), eye problems such as esotropia (akin to Duane syndrome Type I), amblyopia, saccadic smooth pursuit, and myopia (20%), ataxia (10%), autism spectrum disorder (ASD, 10%), hypotonia (10%), and neuropathy (10%). One carrier was diagnosed with schizoaffective disorder and presented with masked facies. It is possible that her masked facies was caused by antipsychotic medication. Other features noted in a single female carrier included seizure disorder and microcephaly.

Two confirmed female carriers who were enrolled, both over age 50, had histories consistent with a neurodegenerative disease, specifically atypical parkinsonism and CBD. Across the full CS cohort of families, including > 30 families, we discerned 2 additional females (likely carriers by pedigree but not confirmed) who, strictly by history, were given diagnoses of CBD or multiple systems atrophy (MSA) after age 50. Neither of these patients was available to be enrolled.

The enrolled and confirmed female carrier diagnosed with CBD was evaluated at approximately age 65. Symptom onset occurred 1–2 years prior with multiple forward falling episodes and gait disturbance. Mental status exam was notable for a rapid cognitive decline, with profound loss of activities of daily living, meaningful language, and communication skills. Dysautonomic symptoms reported included constipation and temperature dysregulation. Neurological exam was notable for masked facies. She had no upward gaze, limited downward gaze, and intact horizontal eye movements. Motor exam showed bradykinesia with abnormal tone demonstrating both cogwheeling and rigidity on her right side. She had a resting tremor at 3–6 Hz that was greater in the right hand, without a postural or intention tremor. Occasional myoclonic jerks were noted. Testing of her reflexes demonstrated hyperreflexia and sustained clonus in both ankles. While she is mostly non-ambulatory, her gait (with assistance) is notable for freezing, brady-

### Table 2. Neurological and neuropsychiatric features of female carriers of NHE6 mutations

| Diagnosis                                      | Carriers, n | Carriers, % (n = 20) | Pedigrees, n | Pedigrees, % (n = 9) |
|------------------------------------------------|-------------|----------------------|--------------|----------------------|
| Intellectual disability (ID)/developmental delay (DD) | 4           | 20                   | 4            | 44                   |
| Learning difficulties (if no ID/DD diagnosis)     | 5           | 31\(^a\)             | 2            | 22                   |
| Speech/language delay                            | 6           | 30                   | 5            | 56                   |
| Attention-deficit/hyperactivity disorder         | 4           | 20                   | 4            | 44                   |
| Schizoaffective disorder                         | 2           | 10                   | 1            | 11                   |
| Autism spectrum disorder                         | 2           | 10                   | 2            | 22                   |
| Seizure disorder                                 | 1           | 5                    | 1            | 11                   |
| Microcephaly                                     | 1           | 5                    | 1            | 11                   |
| Ataxia                                           | 2           | 10                   | 2            | 22                   |
| Hypotonia                                        | 2           | 10                   | 2            | 22                   |
| Neuropathy                                       | 2           | 10                   | 2            | 22                   |
| Eye problems (e.g., ophthalmoplegia)             | 4           | 20                   | 4            | 44                   |

\(^a\) Percentage calculated in 16 participants (i.e., does not include carriers diagnosed with ID/DD).
kinesia, and shuffling. This participant had been diagnosed previously with PSP due to eye movement abnormalities; however, subsequent, and in part due to results from MRI of the brain, the diagnosis was changed to CBD. The MRI scan at age 65 showed asymmetric cortical atrophy (Fig. 3). Specifically, the left frontal and parietal cortical areas were severely atrophic compared to the right hemisphere. Additional notable findings included generalized parenchymal volume loss and increased ventricular size, which was likely due to central volume loss.

We examined a second confirmed female mutation carrier who was diagnosed with parkinsonism at approximately age 55. Symptom onset began in her early 50s, with tremors developing in her right hand and upper limbs that have worsened over time. A brief cognitive screen (i.e., MMSE) indicated intact functioning (score = 27). Examination of cranial nerves demonstrated subtle left eye hypophoria and mild reduction in convergence, as well as the presence of hypomimia and a reduced blink frequency. Motor exam was significant for bradykinesia and abnormalities in tone, including both cogwheeling and gegenhalten. Her reflexes were remarkable for clonus in the right ankle. Her gait was notable for shuffling with reduced arm swing, and she has difficulty turning. This participant had an MRI scan in her early 50s, which indicated generalized brain atrophy and notable cerebellar atrophy (Fig. 4). Cerebellar atrophy was present in both the vermis and hemispheres, and was particularly severe in the vermis. This finding is similar to cerebellar findings in CS male probands [2].

Genomic and Transcriptomic Links between NHE6 and Neurodegeneration

In order to assess a potential role for NHE6 in neurodegeneration, NHE6 expression in postmortem brain was analyzed from two aging and dementia cohorts – ROS [12] and MAP [13]. Demographic and neuropathological information on the 740 participants has been previously reported [14]. To summarize, the mean age at death was 88.0 ± 6.7 years, 471 (63.6%) were female, and 447 (60.4%) met diagnostic criteria for AD. Median Aβ load was 2.2%, while the median tau tangle density was 3.7/mm².

Brain transcriptome analysis examined correlations between aging features and NHE6 expression (Table 3). Decreased NHE6 expression was significantly associated with greater tau tangle density using a strict transcriptome-wide correction (adjusted \( p = 0.05 \)). Without adjusting for multiple corrections, decreased NHE6 expression was further associated with greater Aβ load (uncorrected \( p = 0.04 \)) and decreased cognitive functioning (uncorrected \( p = 0.03 \)). These results did not, however, withstand correction. NHE6 expression was not correlated with neurofibrillary tangles, neuropathological severity, or AD severity. We further investigated correlations using the three main NHE6 isoforms: SLC9A6-001 (Tran-
script ID: ENST00000198689.5), SLC9A6-002 (Transcript ID: ENST00000370698.3), and SLC9A6-003 (Transcript ID: ENST00000370701.1). Notably, increased tau deposition was associated with the SLC9A6-003 isoform (adjusted \( p = 0.03 \)). Finally, we sequenced NHE6 in 156 females diagnosed with Parkinson-related syndromes (e.g., 150 PSP cases and 6 CBD cases) to examine whether NHE6 mutations may be enriched in this cohort (online suppl. Table 1). No deleterious mutations (e.g., nonsense, missense, indel) were identified in this analysis.

**Discussion/Conclusion**

This study outlines novel brain-related phenotypes associated with NHE6 mutations in female carriers from CS pedigrees. Mutations in this gene cause CS in males, an X-linked disorder characterized by ID/DD, epilepsy, postnatal microcephaly, and ataxia with progressive cerebellar atrophy [1]. The current study of 20 female carriers across 9 pedigrees examines the phenotypic range in females with NHE6 mutations with regard to (1) cognitive functioning, (2) neuropsychiatric/medical conditions, and (3) age-associated features. We further examined how alterations in NHE6 brain expression correlate with neurodegenerative variables using large transcriptome datasets derived from normal and pathological aging brains at postmortem. Taken together, our results support novel neuropsychiatric phenotypes related to NHE6 mutations with a spectrum of severity in heterozygous females from CS pedigrees, including potentially age-related pathology.

Although some female carriers in CS pedigrees have previously been reported with ID/DD, speech and language problems, truncal ataxia, hyperkinesis, and psychiatric illness [1–4, 7], we employed standardized neuropsychological measures across multiple CS pedigrees with inherited transmission to rigorously quantify performance across cognitive domains. Our findings suggest that female carriers of NHE6 mutations display a recognizable neurocognitive phenotype. Overall, the majority of assessed female carriers exhibited deficits in at least one cognitive domain (85%), and one-third (31%) had IQ scores < 70. Furthermore, most female carriers of NHE6 mutations demonstrated a recognizable neuropsychological profile, with specific deficits in visuospatial function.
While neurodegenerative features have been reported in CS males and an NHE6 mouse model, the extent to which female carriers may be at risk to develop these symptoms remains an ongoing question that will require larger, longitudinal studies before any conclusive statements can be made. Although we and others [7, 30] have noted cases where aging female carriers in CS pedigrees have been diagnosed with neurodegenerative diseases, it is premature, given the small sample size, to discern whether NHE6 mutations in female carriers represent a bona fide risk or to estimate what the level of risk might be. The current study directly examined 2 female carriers who were >50 years old and were diagnosed with Parkinson-related disorders (e.g., atypical parkinsonism and CBD). Two additional aging females, considered to be likely carriers, were reported by their families to have been diagnosed with neurodegenerative diseases (e.g., CBD and MSA). Again, longitudinal studies consisting of many CS female carriers across multiple pedigrees are necessary to understand whether this cohort is at risk for age-related features or if the reported cases merely reflect false-positives that arise from small sample sizes. We also sought to investigate correlations of NHE6 expression with age-related symptoms. Notably, our analysis of two aging/dementia brain transcriptome datasets (n = 740) provides a different perspective to examine how NHE6 expression is associated with neurodegenerative features in a broader population. This analysis revealed lower NHE6 expression was significantly correlated with increased tau deposition, but not Aβ load, after use of a conservative genome-wide correction. Thus, NHE6 dysfunction may be associated with neurodegenerative symptoms, particularly in tau-related disorders. Note, transcriptional isoform 3 of NHE6 was largely responsible for this finding. Compared to the other NHE6 isoforms, isoform 3 is lacking the first 52 amino acids of NHE6; the protein region absent in isoform 3 includes the N-terminus and part of the first transmembrane domain. It is currently unknown why this isoform is associated with increased tau deposition to a greater extent than the other two isoforms. The clinical diagnoses in females ascertained to date (e.g., CBD, PSP, MSA, and atypical parkinsonism) are often associated with tau deposition. This is particularly true for glial tau inclusions, which, notably, was among the findings in one of the few CS postmortem studies, as was the absence of greater amyloid plaque burden [9]. Given the endosomal function of NHE6, it is plausible to hypothesize that processing and/or clearance of amyloid precursor protein may be altered, which has been suggested by recent published experiments [31, 32]. However, our current study of the large ROS/MAP dataset does not appear to
support this. One additional finding that seems plausible is a risk of cerebellar atrophy in female NHE6 mutation carriers. This finding, as shown in Figure 4, appears to reflect a pattern that is a milder form of cerebellar atrophy, as compared to CS males. This result is also highly consistent with preclinical studies in mouse wherein Sikora et al. [11] identified Purkinje cell loss in female heterozygous mice. However, at this juncture, these interpretations regarding progressive disease in female carriers remain speculative. Also, we did not find evidence of deleterious NHE6 mutations in the DNA collection of females with idiopathic PSP, indicating that these mutations are unlikely to be a common unrecognized cause.

In summary, with regard to neurodegenerative disease, at this time we urge caution in drawing conclusions. However, we believe that our data call attention to this understudied female-specific phenotype, which warrants rigorous follow-up in larger, well-powered studies. NHE6 dysfunction may be associated with age-related features in females, possibly related to parkinsonism or tau-related syndromes. These results support the notion that endosomal proteins are involved in the pathogenesis of both neurodevelopmental and neurodegenerative diseases, and that NHE6-related human disorders may be mixed developmental and degenerative diseases. Nonetheless, follow-up studies in larger, prospectively recruited cohorts, as well as in animal models, are warranted to further define this understudied female-specific condition.

Acknowledgement

The authors would like to thank the families for their participation in the current study. E.M.M. had full access to all the data in the study. This study used samples from the National Institute of Neurological Disorders and Stroke Human Genetics Resource Center DNA and Cell Line Repository (https://catalog.coriell.org/1/ninds), as well as clinical data. Sample numbers correspond-
